Lineage Cell (Israel) Performance
| BTX Stock | ILS 438.50 37.70 7.92% |
On a scale of 0 to 100, Lineage Cell holds a performance score of 4. The company secures a Beta (Market Risk) of -0.88, which conveys possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Lineage Cell are expected to decrease slowly. On the other hand, during market turmoil, Lineage Cell is expected to outperform it slightly. Please check Lineage Cell's sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Lineage Cell's current price movements will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Lineage Cell Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Lineage Cell sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | 11.8 M |
Lineage |
Lineage Cell Relative Risk vs. Return Landscape
If you would invest 39,770 in Lineage Cell Therapeutics on January 25, 2024 and sell it today you would earn a total of 4,080 from holding Lineage Cell Therapeutics or generate 10.26% return on investment over 90 days. Lineage Cell Therapeutics is generating 0.3528% of daily returns assuming 5.7638% volatility of returns over the 90 days investment horizon. Simply put, 50% of all stocks have less volatile historical return distribution than Lineage Cell, and 94% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Lineage Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lineage Cell's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lineage Cell Therapeutics, and traders can use it to determine the average amount a Lineage Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0612
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.76 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.35 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Lineage Cell is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lineage Cell by adding it to a well-diversified portfolio.
Lineage Cell Fundamentals Growth
Lineage Stock prices reflect investors' perceptions of the future prospects and financial health of Lineage Cell, and Lineage Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lineage Stock performance.
| Price To Book | 1.14 X | |||
| Price To Sales | 39.20 X | |||
| Revenue | 4.99 M | |||
| EBITDA | (37.2 M) | |||
| Cash And Equivalents | 27.1 M | |||
| Cash Per Share | 0.18 X | |||
| Total Debt | 5.09 M | |||
| Debt To Equity | 3.10 % | |||
| Book Value Per Share | 1.09 X | |||
| Cash Flow From Operations | (30.88 M) | |||
| Total Asset | 101.66 M | |||
About Lineage Cell Performance
To evaluate Lineage Cell Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Lineage Cell generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Lineage Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Lineage Cell Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Lineage's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. BIOTIME INC operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 76 people.Things to note about Lineage Cell Therapeutics performance evaluation
Checking the ongoing alerts about Lineage Cell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lineage Cell Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lineage Cell had very high historical volatility over the last 90 days | |
| The company reported the revenue of 4.99 M. Net Loss for the year was (45.99 M) with profit before overhead, payroll, taxes, and interest of 4.69 M. | |
| Lineage Cell Therapeutics has accumulated about 27.1 M in cash with (30.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.18. |
- Analyzing Lineage Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lineage Cell's stock is overvalued or undervalued compared to its peers.
- Examining Lineage Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lineage Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lineage Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lineage Cell's stock. These opinions can provide insight into Lineage Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Lineage Stock analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |